Literature DB >> 27156495

Metastasectomy, intralesional resection, or stabilization only in the treatment of bone metastases from renal cell carcinoma.

David W G Langerhuizen1, Stein J Janssen1, Quirine M J van der Vliet1, Kevin A Raskin1, Marco L Ferrone2, Francis J Hornicek1, Joseph H Schwab1, Santiago A Lozano-Calderón1.   

Abstract

BACKGROUND: The mainstay of treatment for bone metastases from renal cell carcinoma is surgery. We assessed if there was a difference in local recurrence, reoperation, and survival between patients who underwent metastasectomy, intralesional curettage, or stabilization only for renal cell carcinoma metastasis to the appendicular skeleton, and if there was a difference in these outcomes based on margin status.
METHODS: This retrospective study included 183 patients; 48% underwent metastasectomy (n = 88, margins: 64 negative; 20 positive; 4 unclear), 30% intralesional curettage (n = 54), and 22% stabilization only (n = 41).
RESULTS: The recurrence rate differed and was highest after stabilization only (39%), followed by intralesional curettage (22%), and metastasectomy (12%) (P = 0.003). However, we found no difference in reoperation rate (P = 0.847). Survival was better in patients who underwent metastasectomy (P = 0.020). The recurrence rate was lower in patients who had a negative margin (5%) as compared to those with a positive margin (26%) (P < 0.001). However, we found no difference in reoperation rate (P = 0.97). Negative margins showed better survival (P < 0.001).
CONCLUSIONS: Our findings emphasize the importance of obtaining negative margins in patients with a good life expectancy, as lower recurrence rate can be attained at a not significant additional risk for reoperation, with a potential impact on survival. J. Surg. Oncol. 2016;114:237-245.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone metastasis; intralesional curettage; metastasectomy; renal cell carcinoma; resection

Mesh:

Year:  2016        PMID: 27156495     DOI: 10.1002/jso.24284

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

Review 1.  [Is surgical treatment ever indicated in metastatic renal cell carcinoma and if so, based on which scientific rationale?]

Authors:  M Burger
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

2.  Outcome after Surgery for Metastases to the Pelvic Bone: A Single Institutional Experience.

Authors:  Chandra Kumar Krishnan; Ilkyu Han; Han-Soo Kim
Journal:  Clin Orthop Surg       Date:  2017-02-13

Review 3.  Role of metastasectomy in the management of renal cell carcinoma.

Authors:  Mark Mikhail; Kevin J Chua; Labeeqa Khizir; Alexandra Tabakin; Eric A Singer
Journal:  Front Surg       Date:  2022-07-29

4.  Clinical features and outcomes of metastatic bone tumors of the pelvis.

Authors:  Qing Yang; Nong Chen; Wenqin Fu
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

5.  Clinical Characteristics and Prognosis of Renal Cell Carcinoma With Spinal Bone Metastases.

Authors:  Jianpo Zhai; Ning Liu; Hai Wang; Guanglin Huang; Libo Man
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.